ArticleAntimicrobial agents and chemotherapy2017
Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 4 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List.Medical mycology · 2024Pooled it
- Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Candida glabrata (Nakaseomyces glabrata): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List.Medical mycology · 2024Pooled it
- Outcomes byAntimicrobial agents and chemotherapy · 2024Trial
- Captive lizards (Squamata: Sauria) as reservoirs of medically important and antifungal-resistant yeasts.Medical mycology · 2026Article
- Comparative Antifungal Activity of Medicinal Plant Extracts and Essential Oils Against Clinical Isolates ofPlants (Basel, Switzerland) · 2026Article
- Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026Review
- Review
- Twenty-Year Course of Antifungal Resistance inJournal of fungi (Basel, Switzerland) · 2025Review
- Unveiling antifungal resistance and biocide tolerance in clinical isolates ofFuture microbiology · 2025Article
- Activity of Rezafungin Against Echinocandin Non-wild typeOpen forum infectious diseases · 2025Article
- Comprehensive Review of Environmental Surveillance for Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Article
- Identification and assessment of antifungal susceptibility ofIranian journal of microbiology · 2024Article
- First Canadian report of transmission of fluconazole-resistantJournal of clinical microbiology · 2024Article
- Antifungal resistance: why are we losing this battle?Future microbiology · 2024Review
- Review
- Whole genome analysis of echinocandin non-susceptible Candida Glabrata clinical isolates: a multi-center study in China.BMC microbiology · 2023Article
- Molecular and Clinical Features of Fluconazole Non-susceptibleAnnals of laboratory medicine · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activity of 7 antifungal agents against 3,557 invasive yeasts and molds collected in 29 countries worldwide in 2014 and 2015 was evaluated. Epidemiological cutoff values (ECVs) published in the Clinical and Laboratory Standards Institute (CLSI) M59 document were applied for species with no clinical breakpoints. Echinocandin susceptibility rates were 95.9% to 100.0% for the 5 most common
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.